Naftin is an anti-fungal drug owned by Sebela Ireland Ltd. It contains the active ingredient naftifine hydrochloride. The drug was first authorized for market use on June 27, 2013 and is available in gel and topical dosage forms.
The generic version of Naftin is expected to be available after January 31, 2033. This is due to the expiration of the drug's last patent on that date.
Naftin is used in the treatment of fungal infections. naftifine hydrochloride, the active ingredient in Naftin, works by inhibiting the growth of fungus.
Naftin holds 6 patents, none of which have expired. The last patent is expected to expire on January 31, 2033. This suggests that the Naftin generic could be released after this date. Below are the details of the patent: